Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/207707
Title: Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1
Author: Mur, Pilar
Viana Errasti, Julen
García Mulero, Sandra
Magraner Pardo, Lorena
Muñoz, Inés G.
Pons, Tirso
Capellá, Gabriel
Pineda, Marta
Feliubadaló, Lidia
Valle, Laura
Keywords: Cèl·lules germinals
Germ Cells
Issue Date: 17-Oct-2023
Publisher: Springer Science and Business Media LLC
Abstract: BackgroundGermline variants affecting the proofreading activity of polymerases epsilon and delta cause a hereditary cancer and adenomatous polyposis syndrome characterized by tumors with a high mutational burden and a specific mutational spectrum. In addition to the implementation of multiple pieces of evidence for the classification of gene variants, POLE and POLD1 variant classification is particularly challenging given that non-disruptive variants affecting the proofreading activity of the corresponding polymerase are the ones associated with cancer. In response to an evident need in the field, we have developed gene-specific variant classification recommendations, based on the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) criteria, for the assessment of non-disruptive variants located in the sequence coding for the exonuclease domain of the polymerases.MethodsA training set of 23 variants considered pathogenic or benign was used to define the usability and strength of the ACMG/AMP criteria. Population frequencies, computational predictions, co-segregation data, phenotypic and tumor data, and functional results, among other features, were considered.ResultsGene-specific variant classification recommendations for non-disruptive variants located in the exonuclease domain of POLE and POLD1 were defined. The resulting recommendations were applied to 128 exonuclease domain variants reported in the literature and/or public databases. A total of 17 variants were classified as pathogenic or likely pathogenic, and 17 as benign or likely benign.ConclusionsOur recommendations, with room for improvement in the coming years as more information become available on carrier families, tumor molecular characteristics and functional assays, are intended to serve the clinical and scientific communities and help improve diagnostic performance, avoiding variant misclassifications.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13073-023-01234-y
It is part of: Genome Medicine, 2023, vol. 15, num. 1
URI: http://hdl.handle.net/2445/207707
Related resource: https://doi.org/10.1186/s13073-023-01234-y
ISSN: 1756-994X
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s13073-023-01234-y.pdf4.67 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons